MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

Summary

Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop cancer cells from growing. This phase I/II trial is studying the side effects and best dose of MDX-010 and to see how well it works in treating patients with recurrent or refractory B-cell non-Hodgkin's lymphoma.

Timeline

Start

2004-06

Primary completion

2008-07

Completion

2009-10

Drugs

Indications